{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T15:17:06Z","timestamp":1795274226506,"version":"4.10.3"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["2024876"],"award-info":[{"award-number":["2024876"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"name":"MRFF Value-Ig Study","award":["2017480"],"award-info":[{"award-number":["2017480"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s40273-026-01664-7","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T17:26:47Z","timestamp":1789493207000},"page":"1555-1571","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Estimating the Healthcare Cost of Infection-Related Hospitalisations in Multiple Myeloma"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9336-5735","authenticated-orcid":false,"given":"Rainier","family":"Arnolda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"},{"role":"corresponding-author","vocabulary":"crossref"}]},{"given":"Sara Carrillo","family":"de Albornoz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Fanning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Irving","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleece","family":"MacPhail","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erica","family":"Wood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoe","family":"McQuilten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis","family":"Petrie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"issue":"8","key":"1664_CR1","doi-asserted-by":"publisher","first-page":"375","DOI":"10.5694\/mja2.50129","volume":"210","author":"DE Joshua","year":"2019","unstructured":"Joshua DE, et al. Biology and therapy of multiple myeloma. Med J Aust. 2019;210(8):375\u201380.","journal-title":"Med J Aust"},{"issue":"3","key":"1664_CR2","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1093\/oncolo\/oyad306","volume":"29","author":"A Rafae","year":"2023","unstructured":"Rafae A, vanRhee F, Al Hadidi S. Perspectives on the treatment of multiple myeloma. Oncologist. 2023;29(3):200\u201312.","journal-title":"Oncologist"},{"issue":"1","key":"1664_CR3","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.amjmed.2022.08.030","volume":"136","author":"J Mikhael","year":"2023","unstructured":"Mikhael J, Bhutani M, Cole CE. Multiple myeloma for the primary care provider: a practical review to promote earlier diagnosis among diverse populations. Am J Med. 2023;136(1):33\u201341.","journal-title":"Am J Med"},{"issue":"15","key":"1664_CR4","doi-asserted-by":"publisher","first-page":"9473","DOI":"10.3390\/ijerph19159473","volume":"19","author":"KMD Merollini","year":"2022","unstructured":"Merollini KMD, et al. Cancer survivors\u2019 long-term health service costs in Queensland, Australia: results of a population-level data linkage study (Cos-Q). Int J Environ Res Public Health. 2022;19(15):9473.","journal-title":"Int J Environ Res Public Health"},{"issue":"9","key":"1664_CR5","doi-asserted-by":"publisher","first-page":"e670","DOI":"10.1016\/S2352-3026(22)00165-X","volume":"9","author":"J Huang","year":"2022","unstructured":"Huang J, et al. The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends. Lancet Haematol. 2022;9(9):e670\u20137.","journal-title":"Lancet Haematol"},{"issue":"2","key":"1664_CR6","doi-asserted-by":"publisher","first-page":"103","DOI":"10.5694\/mja2.52366","volume":"221","author":"Q Luo","year":"2024","unstructured":"Luo Q, et al. Multiple myeloma incidence, mortality, and prevalence estimates and projections, Australia, 1982\u20132043: a statistical modelling study. Med J Aust. 2024;221(2):103\u201310.","journal-title":"Med J Aust"},{"issue":"7","key":"1664_CR7","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1038\/s41375-018-0040-1","volume":"32","author":"H Ludwig","year":"2018","unstructured":"Ludwig H, et al. Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. Leukemia. 2018;32(7):1542\u201360.","journal-title":"Leukemia"},{"issue":"7","key":"1664_CR8","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.clml.2021.02.002","volume":"21","author":"C Lim","year":"2021","unstructured":"Lim C, et al. Epidemiology and risks of infections in patients with multiple myeloma managed with new generation therapies. Clin Lymphoma Myeloma Leuk. 2021;21(7):444-450.e3.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"18","key":"1664_CR9","doi-asserted-by":"publisher","first-page":"4979","DOI":"10.1182\/bloodadvances.2024013461","volume":"8","author":"H Ludwig","year":"2024","unstructured":"Ludwig H, et al. Proposal for harmonizing the reporting of infections during treatment with bispecific antibodies in multiple myeloma. Blood Adv. 2024;8(18):4979\u201382.","journal-title":"Blood Adv"},{"issue":"1","key":"1664_CR10","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3324\/haematol.2024.285645","volume":"110","author":"CH Blimark","year":"2008","unstructured":"Blimark CH, et al. Risk of infections in multiple myeloma. A populationbased study on 8,672 multiple myeloma patients diagnosed 2008-2021 from the Swedish Myeloma Registry. Haematologica. 2008;110(1):163\u201372.","journal-title":"Haematologica"},{"issue":"1","key":"1664_CR11","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1182\/bloodadvances.2022008073","volume":"7","author":"KL Chai","year":"2023","unstructured":"Chai KL, et al. Interventions to reduce infections in patients with hematological malignancies: a systematic review and meta-analysis. Blood Adv. 2023;7(1):20\u201331.","journal-title":"Blood Adv"},{"issue":"1","key":"1664_CR12","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/imj.16279","volume":"54","author":"K Crassini","year":"2024","unstructured":"Crassini K, Gibson J. Pathogenesis and management of immune dysfunction secondary to B cell haematological malignancies. Intern Med J. 2024;54(1):16\u201325.","journal-title":"Intern Med J"},{"issue":"19","key":"1664_CR13","doi-asserted-by":"publisher","first-page":"5898","DOI":"10.1182\/bloodadvances.2023010539","volume":"7","author":"G Reynolds","year":"2023","unstructured":"Reynolds G, et al. Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis. Blood Adv. 2023;7(19):5898\u2013903.","journal-title":"Blood Adv"},{"issue":"11","key":"1664_CR14","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.3390\/ph16111628","volume":"16","author":"S Mor\u00e8","year":"2023","unstructured":"Mor\u00e8 S, et al. Novel immunotherapies and combinations: the future landscape of multiple myeloma treatment. Pharmaceuticals (Basel). 2023;16(11):1628.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"8","key":"1664_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0308812","volume":"19","author":"A Irving","year":"2024","unstructured":"Irving A, et al. Developing and validating a discrete-event simulation model of multiple myeloma disease outcomes and treatment pathways using a national clinical registry. PLoS ONE. 2024;19(8):e0308812.","journal-title":"PLoS ONE"},{"issue":"12","key":"1664_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.7372","volume":"13","author":"J An","year":"2024","unstructured":"An J, et al. Infections associated with CAR-T cell therapy in patients with relapsed refractory multiple myeloma: risks and prevention strategies. Cancer Med. 2024;13(12):e7372.","journal-title":"Cancer Med"},{"issue":"11","key":"1664_CR17","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1007\/s00277-022-04959-9","volume":"101","author":"I Toppila","year":"2022","unstructured":"Toppila I, et al. Comorbidity characteristics of multiple myeloma patients diagnosed in Finland 2005\u20132016. Ann Hematol. 2022;101(11):2485\u201395.","journal-title":"Ann Hematol"},{"issue":"8","key":"1664_CR18","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.1007\/s00277-024-05865-y","volume":"103","author":"K Kysenius","year":"2024","unstructured":"Kysenius K, et al. Comorbidities and survival of multiple myeloma patients diagnosed in Finland between 2000 and 2021. Ann Hematol. 2024;103(8):2931\u201343.","journal-title":"Ann Hematol"},{"issue":"6","key":"1664_CR19","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1111\/ejh.13597","volume":"106","author":"IS Sverrisd\u00f3ttir","year":"2021","unstructured":"Sverrisd\u00f3ttir IS, et al. Comorbidities in multiple myeloma and implications on survival: a population-based study. Eur J Haematol. 2021;106(6):774\u201382.","journal-title":"Eur J Haematol"},{"key":"1664_CR20","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.blre.2019.01.001","volume":"34","author":"C Girmenia","year":"2019","unstructured":"Girmenia C, et al. Management of infectious complications in multiple myeloma patients: expert panel consensus-based recommendations. Blood Rev. 2019;34:84\u201394.","journal-title":"Blood Rev"},{"issue":"2","key":"1664_CR21","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S2352-3026(21)00283-0","volume":"9","author":"NS Raje","year":"2022","unstructured":"Raje NS, et al. Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. Lancet Haematol. 2022;9(2):e143\u201361.","journal-title":"Lancet Haematol"},{"issue":"8","key":"1664_CR22","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1111\/imj.16100","volume":"53","author":"BW Teh","year":"2023","unstructured":"Teh BW, et al. Executive summary of consensus clinical practice guidelines for the prevention of infection in patients with multiple myeloma. Intern Med J. 2023;53(8):1469\u201377.","journal-title":"Intern Med J"},{"issue":"1","key":"1664_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-61144-6","volume":"10","author":"W-S Yang","year":"2020","unstructured":"Yang W-S, et al. Stratified risks of infection-related hospitalization in patients with chronic kidney disease - a prospective cohort study. Sci Rep. 2020;10(1):4475.","journal-title":"Sci Rep"},{"issue":"1","key":"1664_CR24","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1111\/bjh.13532","volume":"171","author":"BW Teh","year":"2015","unstructured":"Teh BW, et al. Risks, severity and timing of infections in patients with multiple myeloma: a longitudinal cohort study in the era of immunomodulatory drug therapy. Br J Haematol. 2015;171(1):100\u20138.","journal-title":"Br J Haematol"},{"issue":"11","key":"1664_CR25","doi-asserted-by":"publisher","first-page":"ofac574","DOI":"10.1093\/ofid\/ofac574","volume":"9","author":"S Vassilopoulos","year":"2022","unstructured":"Vassilopoulos S, et al. Cumulative incidence and relative risk of infection in patients with multiple myeloma treated with anti-CD38 monoclonal antibody-based regimens: a systematic review and meta-analysis. Open Forum Infect Dis. 2022;9(11):ofac574.","journal-title":"Open Forum Infect Dis"},{"key":"1664_CR26","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/413149","author":"S-H Jung","year":"2014","unstructured":"Jung S-H, et al. The impact of hyperglycemia on risk of severe infections during early period of induction therapy in patients with newly diagnosed multiple myeloma. BioMed Res Int. 2014. https:\/\/doi.org\/10.1155\/2014\/413149.","journal-title":"BioMed Res Int"},{"issue":"1","key":"1664_CR27","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1186\/s12957-025-03982-0","volume":"23","author":"J-H Wang","year":"2025","unstructured":"Wang J-H, et al. Impact of type 2 and steroid-induced diabetes mellitus on prognosis in patients with multiple myeloma. World J Surg Oncol. 2025;23(1):330.","journal-title":"World J Surg Oncol"},{"key":"1664_CR28","doi-asserted-by":"publisher","DOI":"10.1200\/GO.22.00068","volume":"8","author":"V Bove","year":"2022","unstructured":"Bove V, et al. Epidemiology and risk factors for the development of infectious complications in newly diagnosed multiple myeloma: a multicenter prospective cohort study in Latin America. JCO Glob Oncol. 2022;8:e2200068.","journal-title":"JCO Glob Oncol"},{"issue":"1","key":"1664_CR29","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/487285","volume":"2013","author":"D Katagiri","year":"2013","unstructured":"Katagiri D, Noiri E, Hinoshita F. Multiple myeloma and kidney disease. Sci World J. 2013;2013(1):487285.","journal-title":"Sci World J"},{"key":"1664_CR30","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025015867","author":"S Carrillo De Albornoz","year":"2025","unstructured":"Carrillo De Albornoz S, et al. Immunoglobulin use, survival, and infection outcomes in patients with chronic lymphocytic leukemia. Blood Adv. 2025. https:\/\/doi.org\/10.1182\/bloodadvances.2025015867.","journal-title":"Blood Adv"},{"issue":"1","key":"1664_CR31","doi-asserted-by":"publisher","DOI":"10.1155\/ah\/5340241","volume":"2025","author":"C Siffel","year":"2025","unstructured":"Siffel C, Davids MS, Anderson-Smits C, Kamieniak M, Ren K, Ardeshir-Rouhani-Fard S, et al. Multiple myeloma and secondary immunodeficiency: a retrospective database analysis assessing burden of infection and treatment patterns. Adv Hematol. 2025;2025(1):5340241.","journal-title":"Adv Hematol"},{"issue":"20","key":"1664_CR32","doi-asserted-by":"publisher","first-page":"5367","DOI":"10.1182\/bloodadvances.2025015867","volume":"9","author":"S Carrillo de Albornoz","year":"2025","unstructured":"Carrillo de Albornoz S, et al. Immunoglobulin use, survival, and infection outcomes in patients with chronic lymphocytic leukemia. Blood Adv. 2025;9(20):5367\u201377.","journal-title":"Blood Adv"},{"issue":"9","key":"1664_CR33","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1182\/bloodadvances.2023012047","volume":"8","author":"S Carrillo de Albornoz","year":"2024","unstructured":"Carrillo de Albornoz S, et al. Economic evaluation: immunoglobulin vs prophylactic antibiotics in hypogammaglobulinemia and hematological malignancies. Blood Adv. 2024;8(9):2259\u201367.","journal-title":"Blood Adv"},{"key":"1664_CR34","unstructured":"National Blood Authority. Report on the issue and use of immunoglobulin. 2014-15 to 2021-22. Cited 2025. https:\/\/www.blood.gov.au\/report-issue-and-use-immunoglobulin."},{"issue":"18","key":"1664_CR35","doi-asserted-by":"publisher","first-page":"4720","DOI":"10.1182\/bloodadvances.2025016490","volume":"9","author":"R Banerjee","year":"2025","unstructured":"Banerjee R, et al. Immunoglobulin prophylaxis should be initiated after bispecific antibody therapy in multiple myeloma, regardless of IgG levels. Blood Adv. 2025;9(18):4720\u20136.","journal-title":"Blood Adv"},{"issue":"1","key":"1664_CR36","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s41669-024-00524-4","volume":"9","author":"M Kosunen","year":"2025","unstructured":"Kosunen M, et al. Healthcare resource utilization and associated costs during the first 5 years after diagnosis and at the end of life: a nationwide cohort study of patients with multiple myeloma in Finland. PharmacoEconomics - Open. 2025;9(1):57\u201368.","journal-title":"PharmacoEconomics - Open"},{"issue":"1","key":"1664_CR37","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1080\/13696998.2022.2133823","volume":"25","author":"M Choon-Quinones","year":"2022","unstructured":"Choon-Quinones M, et al. Beyond medicines\u2019 barriers: exploring the true cost of multiple myeloma. J Med Econ. 2022;25(1):1167\u201375.","journal-title":"J Med Econ"},{"issue":"3","key":"1664_CR38","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/vox.12760","volume":"114","author":"TM Windegger","year":"2019","unstructured":"Windegger TM, et al. Cost\u2013utility analysis comparing hospital-based intravenous immunoglobulin with home-based subcutaneous immunoglobulin in patients with secondary immunodeficiency. Vox Sang. 2019;114(3):237\u201346.","journal-title":"Vox Sang"},{"issue":"10","key":"1664_CR39","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28469","volume":"67","author":"M McCormick","year":"2020","unstructured":"McCormick M, et al. Cost-effectiveness of levofloxacin prophylaxis against bacterial infection in pediatric patients with acute myeloid leukemia. Pediatr Blood Cancer. 2020;67(10):e28469.","journal-title":"Pediatr Blood Cancer"},{"key":"1664_CR40","unstructured":"Department of Health and Human Services. Hospitals and Health Services. Victoria: Victoria State Government. 2022. https:\/\/www.health.vic.gov.au\/hospitals-health-services."},{"key":"1664_CR41","volume-title":"The Australian health care system","author":"SJ Duckett","year":"2004","unstructured":"Duckett SJ. The Australian health care system. 2nd ed. South Melbourne: Oxford University Press; 2004.","edition":"2nd ed"},{"issue":"1","key":"1664_CR42","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s10754-023-09362-z","volume":"24","author":"T Ludlow","year":"2024","unstructured":"Ludlow T, et al. Out-of-pocket expenditure, need, utilisation, and private health insurance in the Australian healthcare system. Int J Health Econ Manag. 2024;24(1):33\u201356.","journal-title":"Int J Health Econ Manag"},{"issue":"6","key":"1664_CR43","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1002\/hec.4811","volume":"33","author":"O Yang","year":"2024","unstructured":"Yang O, Yong J, Zhang Y. Effects of private health insurance on waiting time in public hospitals. Health Econ. 2024;33(6):1192\u2013210.","journal-title":"Health Econ"},{"key":"1664_CR44","unstructured":"Victorian Agency for Health Information. Centre for Victorian Data Linkage. 2023. https:\/\/vahi.vic.gov.au\/ourwork\/data-linkage."},{"key":"1664_CR45","unstructured":"Population Health Research Network. Metadata Platform Victorian Cancer Registry. cited 2025. https:\/\/metadata.phrn.org.au\/dataset\/cancer-vic."},{"key":"1664_CR46","unstructured":"Victorian Legislation. Improving Cancer Outcomes Act 2014. 2014. https:\/\/www.legislation.vic.gov.au\/in-force\/acts\/improving-cancer-outcomes-act-2014\/002."},{"key":"1664_CR47","unstructured":"Population Health Research Network. Metadata Platform Victorian Death Index. cited 2025. https:\/\/metadata.phrn.org.au\/dataset\/deaths-vic."},{"key":"1664_CR48","unstructured":"Independent Health and Aged Care Pricing Authority. ICD-10-AM\/ACHI\/ACS eleventh edition. 2019; Available from: https:\/\/www.ihacpa.gov.au\/resources\/icd-10-amachiacs-eleventh-edition."},{"key":"1664_CR49","unstructured":"Department of Health. Victorian Activity-Based Costing, Victorian Cost Data Collection. 2023. Cited 2025. https:\/\/www.health.vic.gov.au\/data-reporting\/victorian-cost-data-collection-vcdc."},{"issue":"4","key":"1664_CR50","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-026-10551-y","volume":"34","author":"SC de Albornoz","year":"2026","unstructured":"de Albornoz SC, et al. Intravenous versus subcutaneous immunoglobulin in patients with haematological malignancies: time-driven activity-based costing. Support Care Cancer. 2026;34(4):382.","journal-title":"Support Care Cancer"},{"issue":"1","key":"1664_CR51","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.jclinepi.2014.09.017","volume":"68","author":"B Toson","year":"2015","unstructured":"Toson B, Harvey LA, Close JCT. The ICD-10 Charlson comorbidity index predicted mortality but not resource utilization following hip fracture. J Clin Epidemiol. 2015;68(1):44\u201351.","journal-title":"J Clin Epidemiol"},{"key":"1664_CR52","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2147\/CLEP.S438096","volume":"16","author":"T Bothe","year":"2024","unstructured":"Bothe T, et al. Diagnostic validity of chronic kidney disease in health claims data over time: results from a cohort of community-dwelling older adults in Germany. Clin Epidemiol. 2024;16:143\u201354.","journal-title":"Clin Epidemiol"},{"issue":"4","key":"1664_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jeph.2024.202744","volume":"72","author":"A Kuang","year":"2024","unstructured":"Kuang A, et al. Validated administrative data based ICD-10 algorithms for chronic conditions: a systematic review. J Epidemiol Popul Health. 2024;72(4):202744.","journal-title":"J Epidemiol Popul Health"},{"issue":"2","key":"1664_CR54","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0229218","volume":"15","author":"G Philip","year":"2020","unstructured":"Philip G, et al. Validation of a hierarchical algorithm to define chronic liver disease and cirrhosis etiology in administrative healthcare data. PLoS ONE. 2020;15(2):e0229218.","journal-title":"PLoS ONE"},{"issue":"3","key":"1664_CR55","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1159\/000510981","volume":"39","author":"NS Ramrakhiani","year":"2020","unstructured":"Ramrakhiani NS, et al. Validity of International Classification of Diseases, tenth revision, codes for cirrhosis. Dig Dis. 2020;39(3):243\u20136.","journal-title":"Dig Dis"},{"issue":"7","key":"1664_CR56","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000469","volume":"8","author":"LA Swain","year":"2024","unstructured":"Swain LA, et al. Validating new coding algorithms to improve identification of alcohol-associated and nonalcohol-associated cirrhosis hospitalizations in administrative databases. Hepatol Commun. 2024;8(7):e0469.","journal-title":"Hepatol Commun"},{"issue":"5","key":"1664_CR57","doi-asserted-by":"publisher","DOI":"10.1002\/jgh3.70156","volume":"9","author":"JP-E Chang","year":"2025","unstructured":"Chang JP-E, et al. Validation of ICD-10 consensus code set for cirrhosis detection using electronic health records in an Asian population. JGH Open. 2025;9(5):e70156.","journal-title":"JGH Open"},{"issue":"1","key":"1664_CR58","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s12890-024-02909-x","volume":"24","author":"T Howarth","year":"2024","unstructured":"Howarth T, et al. Hospital admission rates and related outcomes among adult Aboriginal Australians with bronchiectasis \u2013 a ten-year retrospective cohort study. BMC Pulm Med. 2024;24(1):118.","journal-title":"BMC Pulm Med"},{"issue":"2","key":"1664_CR59","doi-asserted-by":"publisher","first-page":"00715","DOI":"10.1183\/23120541.00715-2023","volume":"10","author":"ON Green","year":"2024","unstructured":"Green ON, et al. Measuring accuracy of International Classification of Diseases codes in identification of patients with non-cystic fibrosis bronchiectasis. ERJ Open Res. 2024;10(2):00715\u20132023.","journal-title":"ERJ Open Res"},{"issue":"3","key":"1664_CR60","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1080\/03009742.2024.2306716","volume":"53","author":"SA Provan","year":"2024","unstructured":"Provan SA, et al. A validation of register-derived diagnoses of interstitial lung disease in patients with inflammatory arthritis: data from the NOR-DMARD study. Scand J Rheumatol. 2024;53(3):173\u20139.","journal-title":"Scand J Rheumatol"},{"issue":"1","key":"1664_CR61","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1186\/s12913-019-4574-3","volume":"19","author":"H Gothe","year":"2019","unstructured":"Gothe H, et al. Algorithms to identify COPD in health systems with and without access to ICD coding: a systematic review. BMC Health Serv Res. 2019;19(1):737.","journal-title":"BMC Health Serv Res"},{"key":"1664_CR62","unstructured":"Australian Institute of Health and Welfare. Validating algorithms for incidence of cardiovascular disease. 2022. https:\/\/www.aihw.gov.au\/getmedia\/9ab3cc72-f035-4a82-b9d2-dc3d2bf4ab27\/aihw-cdk-21_technical-report.pdf."},{"issue":"2","key":"1664_CR63","first-page":"61","volume":"53","author":"GJ Duke","year":"2024","unstructured":"Duke GJ, et al. Performance of hospital administrative data for detection of sepsis in Australia: the sepsis coding and documentation (SECOND) study. Health Inf Manag J. 2024;53(2):61\u20137.","journal-title":"Health Inf Manag J"},{"key":"1664_CR64","unstructured":"Australian Bureau of Statistics. Consumer Price Index, Australia. 2024 [cited 2024 2025]. https:\/\/www.abs.gov.au\/statistics\/economy\/price-indexes-and-inflation\/consumer-price-index-australia\/sep-quarter-2024."},{"key":"1664_CR65","unstructured":"Evidence for Policy & Practice Information Centre. CCEMG\u2013EPPI Centre Cost Converter v.1.7. 2024 January 2024 [cited 2025]. https:\/\/eppi.ioe.ac.uk\/costconversion\/."},{"issue":"8","key":"1664_CR66","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1002\/hec.1653","volume":"20","author":"B Mihaylova","year":"2011","unstructured":"Mihaylova B, et al. Review of statistical methods for analysing healthcare resources and costs. Health Econ. 2011;20(8):897\u2013916.","journal-title":"Health Econ"},{"issue":"3","key":"1664_CR67","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s40273-023-01319-x","volume":"42","author":"J Zhou","year":"2024","unstructured":"Zhou J, et al. Estimating costs associated with disease model states using generalized linear models: a tutorial. Pharmacoeconomics. 2024;42(3):261\u201373.","journal-title":"Pharmacoeconomics"},{"key":"1664_CR68","unstructured":"BloodStar. Criteria for clinical use of immunoglobulin in Australia: acquired hypogammaglobulinaemia secondary to haematological malignancies, or post-haemopoietic stem cell transplantation (hscT). 2025 [cited 2025; 3.5]. https:\/\/www.criteria.blood.gov.au\/MedicalCondition\/View\/2720."},{"key":"1664_CR69","doi-asserted-by":"publisher","first-page":"4725","DOI":"10.1182\/blood-2019-130791","volume":"134","author":"G Felber","year":"2019","unstructured":"Felber G, et al. US cost burden of relapsed refractory multiple myeloma during third and later lines of treatment. Blood. 2019;134:4725.","journal-title":"Blood"},{"issue":"5","key":"1664_CR70","doi-asserted-by":"publisher","first-page":"e221229","DOI":"10.1001\/jamahealthforum.2022.1229","volume":"3","author":"RD Chow","year":"2022","unstructured":"Chow RD, Bradley EH, Gross CP. Comparison of cancer-related spending and mortality rates in the US vs 21 high-income countries. JAMA Health Forum. 2022;3(5):e221229.","journal-title":"JAMA Health Forum"},{"issue":"8","key":"1664_CR71","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0255107","volume":"16","author":"M Tew","year":"2021","unstructured":"Tew M, et al. Excess cost of care associated with sepsis in cancer patients: results from a population-based case-control matched cohort. PLoS ONE. 2021;16(8):e0255107.","journal-title":"PLoS ONE"},{"key":"1664_CR72","unstructured":"Australian Institute of Health and Welfare. Heart, stroke and vascular disease: Australian facts. 2024 [cited 2025]. https:\/\/www.aihw.gov.au\/reports\/heart-stroke-vascular-diseases\/hsvd-facts\/contents\/about."},{"issue":"5","key":"1664_CR73","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1111\/dom.16271","volume":"27","author":"J Pearson-Stuttard","year":"2025","unstructured":"Pearson-Stuttard J, et al. Estimating healthcare resource utilisation and cardiovascular events in people with high body mass index and established cardiovascular disease. Diabetes Obes Metab. 2025;27(5):2690\u20137.","journal-title":"Diabetes Obes Metab"},{"key":"1664_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2024.102676","volume":"93","author":"RJ Mitchell","year":"2024","unstructured":"Mitchell RJ, et al. Three-year hospital service use trajectories of people diagnosed with cancer: a retrospective cohort study. Cancer Epidemiol. 2024;93:102676.","journal-title":"Cancer Epidemiol"},{"issue":"5","key":"1664_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinme.2025.100497","volume":"25","author":"V Palin","year":"2025","unstructured":"Palin V, et al. Infection in people with heart failure: an overlooked cause of adverse outcomes. Clin Med. 2025;25(5):100497.","journal-title":"Clin Med"},{"issue":"10","key":"1664_CR76","doi-asserted-by":"publisher","first-page":"e0539","DOI":"10.1097\/HC9.0000000000000539","volume":"8","author":"J Ferguson Toll","year":"2024","unstructured":"Ferguson Toll J, et al. Infections in decompensated cirrhosis: pathophysiology, management, and research agenda. Hepatol Commun. 2024;8(10):e0539.","journal-title":"Hepatol Commun"},{"issue":"1","key":"1664_CR77","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.pcrj.2005.10.004","volume":"15","author":"ML Levy","year":"2006","unstructured":"Levy ML, et al. International Primary Care Respiratory Group (IPCRG) guidelines: diagnosis of respiratory diseases in primary care. Prim Care Respir J. 2006;15(1):20\u201334.","journal-title":"Prim Care Respir J"},{"issue":"S6","key":"1664_CR78","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.5694\/j.1326-5377.2003.tb05213.x","volume":"178","author":"DK McKenzie","year":"2003","unstructured":"McKenzie DK, Frith PA. The COPDX Plan: Australian and New Zealand guidelines for the management of chronic obstructive pulmonary disease 2003. Med J Aust. 2003;178(S6):S1\u201339.","journal-title":"Med J Aust"},{"issue":"17","key":"1664_CR79","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70201","volume":"13","author":"KMD Merollini","year":"2024","unstructured":"Merollini KMD, et al. Factors impacting hospitalisation and related health service costs in cancer survivors in Australia: results from a population data linkage study in Queensland (COS-Q). Cancer Med. 2024;13(17):e70201.","journal-title":"Cancer Med"},{"issue":"5","key":"1664_CR80","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/hcs2.112","volume":"3","author":"M Baazeem","year":"2024","unstructured":"Baazeem M, Kruger E, Tennant M. Are private hospital emergency departments in Australia distributed to serve the wealthy community? Health Care Sci. 2024;3(5):287\u201397.","journal-title":"Health Care Sci"},{"issue":"6","key":"1664_CR81","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1111\/1742-6723.12841","volume":"29","author":"J He","year":"2017","unstructured":"He J, et al. Patients\u2019 choice between public and private hospital emergency departments: a cross-sectional survey. Emerg Med Australas. 2017;29(6):635\u201342.","journal-title":"Emerg Med Australas"},{"issue":"6","key":"1664_CR82","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/ejh.13223","volume":"102","author":"I-K Na","year":"2019","unstructured":"Na I-K, et al. Current clinical practice and challenges in the management of secondary immunodeficiency in hematological malignancies. Eur J Haematol. 2019;102(6):447\u201356.","journal-title":"Eur J Haematol"},{"issue":"4","key":"1664_CR83","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1097\/MLR.0000000000000330","volume":"53","author":"T Blakely","year":"2015","unstructured":"Blakely T, et al. Patterns of cancer care costs in a country with detailed individual data. Med Care. 2015;53(4):302\u20139.","journal-title":"Med Care"},{"issue":"7","key":"1664_CR84","doi-asserted-by":"publisher","first-page":"e2116357","DOI":"10.1001\/jamanetworkopen.2021.16357","volume":"4","author":"K Bhattacharya","year":"2021","unstructured":"Bhattacharya K, et al. Phase-specific and lifetime costs of multiple myeloma among older adults in the US. JAMA Netw Open. 2021;4(7):e2116357.","journal-title":"JAMA Netw Open"},{"issue":"4","key":"1664_CR85","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.bbmt.2019.12.772","volume":"26","author":"N Dunavin","year":"2020","unstructured":"Dunavin N, et al. Health care reimbursement, service utilization, and outcomes among Medicare beneficiaries with multiple myeloma receiving autologous hematopoietic cell transplantation in inpatient and outpatient settings. Biol Blood Marrow Transplant. 2020;26(4):805\u201313.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"1664_CR86","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41408-021-00431-5","volume":"11","author":"R Fonseca","year":"2021","unstructured":"Fonseca R, et al. Economic burden of disease progression among multiple myeloma patients who have received transplant and at least one line of therapy in the US. Blood Cancer J. 2021;11(2):35.","journal-title":"Blood Cancer J"},{"issue":"8","key":"1664_CR87","first-page":"917","volume":"29","author":"J Yang","year":"2023","unstructured":"Yang J, et al. Health care resource utilization and costs among patients with multiple myeloma with exposure to double-class or triple-class multiple myeloma treatments: a retrospective US claims database analysis. J Manag Care Spec Pharm. 2023;29(8):917\u201326.","journal-title":"J Manag Care Spec Pharm"},{"issue":"4","key":"1664_CR88","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1002\/jha2.798","volume":"4","author":"DB Bayani","year":"2023","unstructured":"Bayani DB, et al. Real-world utilization and healthcare costs for multiple myeloma: a retrospective analysis of patients in Singapore. EJHaem. 2023;4(4):1013\u20138.","journal-title":"EJHaem"},{"issue":"6","key":"1664_CR89","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000913","volume":"7","author":"C Bennink","year":"2023","unstructured":"Bennink C, et al. High hospital-related costs at the end-of-life in patients with multiple myeloma: a single-center study. HemaSphere. 2023;7(6):e913.","journal-title":"HemaSphere"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-026-01664-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-026-01664-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-026-01664-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T15:01:51Z","timestamp":1795273311000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-026-01664-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":89,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["1664"],"URL":"https:\/\/doi.org\/10.1007\/s40273-026-01664-7","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]},"assertion":[{"value":"8 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The following authors declare no conflict of interest: Rainier Arnolda, Sara Carrillo de Albornoz, Laura Fanning, Aleece MacPhail, Adam Irving and Dennis Petrie. The following authors declare conflict of interest: Erica Wood and Zoe McQuilten received grant funding from CSL Behring, not related to this study, and research funding to the institution from AbbVie, Amgen, AstraZeneca, BeiGene, Celgene, Janssen, Novartis, Sanofi and Takeda. Andrew Spencer has received consultancy fees from Rheumagen, Celltrion, Haemalogix, BMS and Janssen; honoraria from Haemalogix, Sanofi, Antengene, Thermofisher, BMS, Janssen, Roche, AbbVie and Pfizer; research funding from Haemalogix, Antengene, Janssen and AbbVie, not related to this study; serves on speakers\u2019 bureaus for Sanofi, Thermofisher, BMS, Janssen and Pfizer; and serves on advisory committees for Haemalogix, Sanofi, Antengene, BMS, Janssen, Roche and Pfizer.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was granted by the Monash University Human Research Ethics Committee (MUHREC) (project ID 40164).","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval included a waiver of individual consent as de-identified administrative data were used. The datasets were unlinked to external sources and were used for population-level analyses, with confidentiality safeguards in place.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication (from Patients\/Participations)","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The data included in this article were provided via an application process by the Centre for Victorian Data Linkage (CVDL) and are not publicly available. An online application can be made to CVDL via:\n                      \n                      .","order":5,"name":"Ethics","label":"Data Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The code used in the data management and analysis can be made available upon reasonable request to the authors.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"R.A., S.C.A. and D.P. designed the study. R.A. conducted the data analysis, interpreted the results and wrote this manuscript. L.F. prepared the HREC submission, led the data acquisition with contributions from A.I. and D.P. and contributed to the data analysis. S.C.A. contributed to the data analysis. D.P., A.I. and L.F. guided the data analysis process, assisted in refining the analytical approach and advised on the interpretation and contextualisation of results. A.M., E.W., Z.M. and A.S. provided key clinical input and advice. All authors reviewed and approved the final version of this paper.","order":7,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}